Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:59 PM
Ignite Modification Date:
2025-12-24 @ 7:59 PM
NCT ID:
NCT02123004
Eligibility Criteria:
Inclusion Criteria:
1. Male or non-pregnant female.
2. Age ≥ 18 years old and \<80 years old.
3. Consecutive patients who should be hospitalized with documented evidence of ST-Segment Elevation Myocardial Infarction receiving Percutaneous Coronary Intervention.
4. All patients havepersistent≥0.2 Millivolt ST segment elevation in two or more contiguous precordial leads or ≥0.1 Millivolt ST elevation in two or more contiguous limb leads, with one of the following: persistent chest pain or elevatory of biomarkers of myocardial necrosis.
5. Time from chest pain onset to receiving Percutaneous Coronary Intervention \<12 hours.
6. Persistent chest pain \<12 hours.
7. Provision of informed consent prior to any study specific procedures.
Exclusion Criteria:
1. Involved in other trials.
2. In recent one year have P 2 Y 12 receptor antagonist drug treatment history or long-term use of immunosuppressive agents.
3. Recurrent myocardial infarction or previous history of Coronary Artery Bypass Graft(CABG) surgery or rescue Percutaneous Coronary Intervention.
4. Active bleeding or bleeding history.
5. With obvious infection and body temperature (axillary temperature) higher than 38.0 ℃.
6. Autoimmune diseases.
7. Malignancies.
8. In recent 6 months have received major surgery.
9. Left ventricular ejection fraction is less than 30%.
10. Life expectancy less than one year.
11. With moderate and severe liver function deterioration.
12. End-stage renal failure.
13. Other conditions that may put the patient at risk or influence study results in the investigators' opinion：eg, increased risk of bradycardiac events; known clinically important thrombocytopenia; known clinically important anemia; severe hemodynamic instability.
14. Other contraindications to investigate products.
15. Any condition that increases the risk for noncompliance or being lost to follow-up.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT02123004
Study Brief:
Protocol Section:
NCT02123004